ImaBiotech website in English


  • ASMS 2017

    Come and meet Rima Ait-Belkacem and Jonathan Stauber to discover all our capabilities. June 4- 8, 2017, in (...)

    Read more
  • Webinar on Immuno-Oncology by Rima AIT-BELKACEM, PhD

    The webinar titled “Immuno-Oncology: Tryptophan-Kynurenine Microenvironment Tumor Metabolites Pathway Highlighted by (...)

    Read more
See all news

Central Nervous System

ImaBiotech provides quantitative MALDI Imaging Mass Spectrometry services unmatched by any other classical technique: quantitative label-free CNS distribution with high accuracy up to 20µm resolution.

Classical drug pharmacokinetics, such as the evaluation of the brain/plasma ratio of molecule concentration, can now be advantageously replaced by MALDI Imaging Mass Spectrometry, which offers accurate localization and quantitation of parent drugs and metabolites. The evaluation of regio-distribution in the brain also supports studies in pharmacology and local toxicity, side effects, etc..

In the same experiment, MALDI Imaging Mass Spectrometry can also provide valuable information regarding endogenous metabolites (lipids, proteins,…) and disease markers such as amyloid peptides.

Central Nervous System _ _

Figure : Distribution of drug in longitudinal brain section, before & after normalization with concentrated drug compound in 3rd Ventricule (Quantitation has been validated with LCMS² quantiatition)
(a) Calibration curve obtained for previous drug dilution range.
(b) Quantification of previous drug in specific region of brain (hippocampus) using QMSI (TEC calculation) validated by LC-MC/MS

In Central Nervous systems, we can study :
Target Engagement


Toxicity effects with Mass Spectrometry Imaging ImaBiotechToxicity effects

Drug distribution and quantification
  • High resolution drug and metabolites imaging at 20µm
  • Quantify drug and metabolites in various regions of the brain
  • Coupled with whole body distribution to study overall and organ-specific localization
  • Combined with Biomarker imaging (Beta Amyloid 1-42, 1-38...)
  • Unknown metabolite research and identification

  • Alzheimer and Parkinson disease
  • Psychotropic diseases
  • Pain

Regions of interest
  • Hippocampus
  • Cerebellum
  • Cortices
  • Corpus callosum
  • Blood-brain barrier

  • Study the impact of treatment onto endogenous metabolites
  • Support the validation of pharmacological animal models